Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

The move targets thimerosal, a preservative that anti-vaccine activists blame for neurodevelopmental disorders, despite ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

The new guidance on vaccines, such as those that protect against COVID-19, influenza, and RSV, will be released by the end of the summer, ahead of respiratory season.

Health and Human Services Secretary Robert F. Kennedy Jr. ordered that thimerosal, a mercury-based preservative, be removed from US flu shots based on a recommendation from an influential vaccine ...

N.B.1.8.1, dubbed “razor blade throat,” is the current dominant variant in the U.S. It's an offshoot of XVD.1.5.1, which is a ...

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective study published in the Journal of the American ...